Purpose: The main prognostic factor of lung cancer patient outcome is clinical stage, a parameter of tumor aggressiveness. Our study was conducted to test whether germ line variations modulate individual differences in clinical stage.
Introduction
Lung cancer prognosis is affected by clinical stage, tumor histologic subtype, and the possibility of surgical resection. However, clinical stage is the parameter with the greatest impact on lung cancer patient survival; indeed, patients with early-stage cancer have an excellent prognosis, whereas prognosis is poorer with increasing stage (reviewed in ref. 1) .
Variations in cancer aggressiveness and malignancy have been associated mainly with the accumulation of multiple somatic alterations and epigenetic changes in the neoplastic cells (2) . While most studies aimed at identifying factors that affect cancer patient outcome/survival have focused on genetic alterations or transcriptional changes in the cancer tissue, a recent study suggests a role for germ line variations in the control of lung cancer patient survival (3) . Those findings are supported by results in mouse models of lung tumorigenesis showing that specific genetic loci modulate tumor progression (4, 5) .
In the present study, we conducted a genome-wide association study (GWAS) of lung adenocarcinoma (ADCA) patients to test the hypothesis that clinical stage can be genetically modulated. Comparison of DNA from patients at clinical stage I with DNA of patients at higher clinical stages revealed multiple and unlinked singlenucleotide polymorphisms (SNPs) that may genetically modulate clinical stage and that together are associated with patient overall survival.
Materials and Methods

Study population and DNAs
All patients were enrolled in the authors' institutes in Milan, Italy (Table 1) . Study protocols were approved by all ethics committees, and each subject gave informed consent to the use of their biological samples for research purposes.
Genomic DNA was extracted from peripheral blood using the DNeasy Blood & Tissue Kit (QIAGEN) and quantified by fluorimetry using the Picogreen dsDNA Quantitation Kit (Invitrogen).
Patients in the first series were divided into 2 groups according to clinical stage (I or >I), and the same amounts of each DNA sample were used to create a DNA pool of 300 stage I patients and a DNA pool of 300 patients at higher clinical stages. Since the accuracy of analyses using a DNA pooling strategy depends heavily on the estimates of DNA concentration (6), we performed serial dilutions of each DNA sample.
SNP array and genotyping
A genome-wide DNA pooling strategy was used for initial screening to minimize interindividual sample variability and to reduce costs and time as compared with analyses of individual samples at the same power of study and with a robust estimation of allele frequency (7) . Putative associations were confirmed by individual genotyping.
DNA pools were analyzed using the Human610-Quad BeadChip array (Illumina), which allows analysis of 620,901 genetic markers chosen from the International HapMap release 23. Twelve SNP array hybridizations were performed for each DNA pool to verify genotype reproducibility and to estimate technical variability. Data were obtained as intensity signals used to determine allele frequencies of each SNP and to reconstruct the number of chromosomes carrying each of the 2 possible alleles. Selected SNPs were genotyped in individual samples using MassARRAY (Sequenom) as described (8) .
Statistical analysis
Differences between stage I and stage >I lung ADCA cases in allelic frequencies assessed in SNP array hybridization were analyzed using random variance t statistics and BRB ArrayTools (http://linus.nci.nih.gov/BRBArrayTools.html). Differences in chromosome counts between the 2 groups were tested by Fisher's exact test or by c 2 analysis when the normal approximation was appropriate. The correlation between SNP array and individual genotype allelic frequencies was expressed as a Pearson's coefficient. Association between clinical stage (I or >I) and confounding variables was analyzed using ANOVA or logistic analysis, whereas association between SNPs and clinical stage was analyzed using PLINK software (9) , which included analysis of Hardy-Weinberg equilibrium (HWE), linkage disequilibrium (LD) between SNPs, and population-based association between prognosis factors and genotype/allelotype. Age at cancer diagnosis was downcoded to binary dummy variables (age in decades), which were used as covariates in logistic regression analyses. The average genetic risk score of clinical stage >1 for individuals was calculated using the "score" procedure of PLINK, that is, the sum, across the 22 significantly (P < 0.01) associated SNPs in the joint analysis, of the number of minor alleles (0, 1, or 2) at any SNP multiplied by the log of the OR for that SNP. The reliability of the model was assessed by bootstrap resampling with replacement (10). Overall survival was assessed using Cox regression analysis and the "survival" package in R, with follow-up cutoff at 60 months to reduce bias due to mortality caused by non-cancer-related factors. All statistical tests were 2-sided.
Results
GWAS identifies multiple SNPs associated with clinical stage
Genome-wide SNP array analysis conducted in 12 replicas of DNA pools from lung ADCA cases at clinical stage I or at higher clinical stages, respectively, allowed the screening of 620,901 SNPs. After discarding SNPs whose minor allele frequency was less than 0.10 in the pools and whose statistically significant imbalance of allelic frequencies between the 2 DNA pools was below the genome-wide threshold of P 2.0 Â 10
À6
, analysis of the reconstructed number of chromosomes of the remaining SNPs in the 2 groups using a 2 Â 2 contingency table revealed 80 most statistically associated SNPs (P < 1.0 Â 10
À4
). These were selected for individual genotyping to validate the SNP array findings in the DNA pool. Of the 80 SNPs, 2 mitochondrial SNPs, 1 SNP on chromosome Y, and 9 redundant SNPs in tight LD with close-by SNPs (<58-kb distance) in the same locus in the HapMap Caucasian (CEU) population were excluded; 1 SNP failed PCR or MassEXTEND primer design and 4 additional SNPs failed genotyping, reducing the number of markers to 63 SNPs.
A good correlation was observed in the minor allele frequencies obtained either by MassARRAY genotyping in single individuals or by SNP array analysis in DNA pools
Translational Relevance
Clinical stage is the main clinical parameter affecting prognosis in lung cancer patients. We tested whether a genetic component might be involved in modulating patient clinical stage. In 917 Italian lung adenocarcinoma patients, we detected 22 genetic variants that together explained a large individual variation in clinical stage and that were also associated with overall survival. This demonstration that individual genetic constitution can affect clinical stage represents a step toward understanding the role of genetic factors in a clinically relevant parameter and opens the possibility of identifying new genetic targets for lung cancer therapy based on individual genetic constitution. 
), demonstrating the reliability of the DNA pooling approach. None of the selected SNPs showed significant deviation from the HWE, except for rs565968 (P ¼ 0.00076). No statistically significant LD was observed between any SNP pairs (r 2 < 0.1). Association analysis using a logistic model, adjusted for age at diagnosis and smoking status, indicated that 54 of 63 SNPs were statistically associated with clinical stage status ( Table 2 , P < 0.05). The strongest association was observed for SNP rs10278557 (P ¼ 5.0 Â 10 À6 ), which maps in the mesenchyme homeobox 2 (MEOX2) gene on chromosome 7.
Among the 63 SNPs tested in the replication series of 317 lung ADCA samples (Table 1) , 3 SNPs showed replication in the independent smaller ADCA series (Table 3) . Joint analysis of the GWA and replication series, increasing the statistical power of association analyses (11) and bringing the total sample size to 917 lung ADCA patients, revealed no statistically significant deviation (P < 0.01) from the HWE for any of the 63 SNPs and identified 22 SNPs significantly associated with clinical stage at the statistical threshold of P < 0.01 by logistic analysis adjusted for age at diagnosis and smoking status ( Table 4 ). The strongest Subjects were divided into quartiles on the basis of the genetic risk score. Application of the generalized linear model to the quartile groups, with the lowest quartile as the reference, revealed a significant association between the genetic estimator and increased probability of developing a more aggressive lung ADCA (OR ¼ 2.9, 95% CI ¼ 1.9-4.6, P ¼ 2.7 Â 10 À6 for the second quartile, OR ¼ 6.8, 95%
CI ¼ 4.4-10.7, P < 2 Â 10 À16 for the third quartile; and OR ¼ 14.5, 95% CI ¼ 9.1-23.6, P < 2 Â 10 À16 for the fourth quartile group, Fig. 1A) . Finally, Kaplan-Meier curves showed a statistically significant association between the genetic risk score, in quartiles, and overall survival (P ¼ 8.0 Â 10 À8 , log-rank test; Fig. 1B) . Use of multivariate Cox proportional hazard models for survival (adjusted for age and smoking habit) to evaluate the association between the genetic risk score and overall survival showed that the risk of death for quartiles 3 and 4 (HR ¼ 1.
, respectively) was significantly higher than that of the lowest quartile.
Discussion
In recent years, several GWAS have focused on genetic risk for lung cancer, but none has examined the possible genetic modulation of the most powerful prognostic factor in lung cancer patients, that is, clinical stage (1). Our present study in a patient series of the same lung cancer histotype and of the same ethnicity identified 54 SNPs, putatively associated (P < 0.05) with clinical stage (Table 2 ) in a relatively large first series of 600 patients, and 3 SNPs that maintained their statistical association with clinical stage in the smaller replication series (Table 3 ). Joint analysis of the GWAS and replication series to increase the statistical power of the study and to obtain an overall unbiased estimate (11) identified 22 SNPs that, at nominal statistical value of P < 0.01, showed statistical association with clinical stage (Table 4) . Analysis of additive effects of risk associated to the minor alleles of these 22 SNPs using a polygenic model (8) revealed a statistically significant association between the genetic estimator and an increased risk of higher clinical stage (Fig. 1A ) and higher risk of death (Fig. 1B) , suggesting the complex genetic control of lung ADCA patient clinical prognosis.
Of the 22 candidate SNPs, 6 mapped within genes. The most significantly associated SNP in the joint analysis (rs10278557, P ¼ 1.1 Â 10 À5 , Table 4 ) maps on chromosome 7 in the intronic region of the MEOX2 gene, also known as growth arrest-specific homeobox (GAX) gene, a member of a subfamily of nonclustered, divergent, antennapedia-like homeobox-containing genes. MEOX2, a key regulator of vascular cell function, has been proposed as a candidate tumor suppressor gene in Wilm's tumor and shows upregulation and aberrant methylation in lung cancer (12, 13) . The myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila; MLL5, rs2299297), the sprouty related, EVH1 domain containing 1 (SPRED1, rs10520058), and the WW domain containing oxidoreductase (WWOX, rs10514440; Table 4 ) candidacies are also of interest. Indeed, the MLL5 gene belongs to a gene family that activates and regulates homeobox (HOX) genes that are important in oncogenesis and tumor suppression (14, 15) . MLL5 is located on chromosome 7q22, which is frequently deleted in myeloid leukemias and is a key regulator of normal hematopoiesis (16) . SPRED1 negatively regulates the Ras-ERK (extracellular signal-regulated kinases) signaling pathway, cell motility, and metastasis, and its germ line loss-of-function mutations cause a neurofibromatosis 1-like syndrome (17, 18) . WWOX acts as a tumor suppressor gene in different tumor types and plays a regulatory role in protein degradation, transcription, and RNA splicing (reviewed in ref. 19 ).
At present, it is unknown whether the observed associations between SNPs and lung cancer clinical stage underlie effects of nonsynonymous or regulatory variants in LD with these SNPs.
Empirical replication using bootstrap samples from the original data, rather than replication in independent samples, has been proposed in association studies since bootstrap samples likely share the same population structure of original data, whereas an independent series may be characterized by a different population structure and, thus, lead to false-negative results on analysis (20) . Our empirical replication using bootstrap samples confirmed the statistically significant difference between stage I and stage >I patients in their genetic estimator on the basis of 22 SNPs. However, the lack of a replica in a truly independent population remains a potential weakness of the present study that may be overcome in future, large studies carried out by international consortia.
Together, our results indicate for the first time that clinical staging of lung ADCA can be under genetic control, with each patient displaying a tendency toward a low or high clinical stage depending on individual genetic variations. The significant association of the 22 SNPs with lung ADCA clinical stage and survival raises the possibility that the functional products of the genes linked to these SNPs use novel biochemical pathways associated with such patient outcome, and that identification of these pathways might provide gene targets for therapies to counter disease progression. Further clarification of the role of genetic mechanisms in lung ADCA patient outcomes may hold the promise of improved therapy and disease outcome.
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